News

Welcome to the second Innovation Magazine from the UCLA Technology Development Group. In this issue we highlight UCLA TDG accomplishments in recent months! Our many projects are fully under way and we have established partnerships at multiple levels within the UC ecosystem, investors and with industry professionals. Featured in this issue of the magazine is storytelling and background on the TDG team, our recent deal making, what we do and how we’ve arrived at our success and growth.

Eighteen professors, researchers and clinicians at UCLA have been named recipients of awards from the 2017 UCLA Innovation Fund Biomedical Competition, which was established to quickly move technologies from idea to the marketplace and bridge the gap between academia and industry-investor interest to provide benefit to patients and the public.

Falcon Computing Solutions and the UCLA Center for Precision Medicine today announced a collaboration that will accelerate innovation and the adoption of cloud-based genomics sequencing solutions. Falcon is conducting initial product testing, benchmarking and optimization at UCLA based on the industry standard GATK best practices pipeline, and is receiving valuable feedback from the UCLA researchers and scientists that allow for product optimization. The joint activity builds upon an existing relationship between UCLA and Falcon – a UCLA spinout co-founded by Dr.

The trial investigated the effects of eTNS on ADHD as the sole treatment, or "monotherapy." A total of 62 children were enrolled in the trial and used the eTNS therapy each night, at home, for four weeks. The trial's primary endpoint assessment, the ADHD-RS, showed that subjects randomized to active treatment had a statistically significant improvement in their ADHD symptoms compared with the sham group (p = 0.005). The CGI-I scale, a secondary endpoint, also demonstrated statistically significant improvements in ADHD symptoms among subjects randomized to the treatment group (p = 0.003).